Skip to main content
. Author manuscript; available in PMC: 2024 Jun 6.
Published before final editing as: Gut. 2022 Dec 6:gutjnl-2022-328174. doi: 10.1136/gutjnl-2022-328174

Figure 2.

Figure 2.

Risk and PAR of Crohn’s disease according to baseline modifiable risk score for (a) pooled NHS/NHSII/HPFS cohort, (b) pooled SCM/CoSM cohort, and (c) EPIC cohort. aNSAID data missing from external cohorts, thus maximum MRS = 5. bCox models adjusted for baseline age (years) and cohort. cPAR for 2+ risk factors compared to reference (0–1), adjusted for age (<40, 40 ≤ age <60, ≥ 60 years) and cohort. CD Crohn’s Disease. CI Confidence Interval. CoSM Cohort of Swedish Men. EPIC European Prospective Investigation into Cancer and Nutrition. HPFS Health Professional’s Follow-up Study. aHR Multivariable-adjusted Hazard Ratio. MRS Modifiable Risk Score. NHS Nurses’ Health Study. PAR Population Attributable Risk. SMC Swedish Mammography Cohort.